Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial

While a phase III study did not find a significant improvement in overall survival of Asian patients with advanced #StomachCancer treated with olaparib, the data collected will provide initial information for further studies.